Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 2, 2015, Pages 123-130

  Jinushi, Masahisa ^a,b   Komohara, Yoshihiro ^c  

^a School of Medicine Graduate School of Medicine   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Anti cancer therapy; CSF 1 receptor inhibitor; Tumor microenvironments; Tumor associated macrophages

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLZ 945; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; EMACTUZUMAB; FLUOROURACIL; GEMCITABINE; IMATINIB; OXALIPLATIN; PACLITAXEL; PLX 3397; RAPAMYCIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; ANTIBODIES, MONOCLONAL, HUMANIZED; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CELL DEATH; COLORECTAL CARCINOMA; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTATIC COLORECTAL CANCER; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOFT TISSUE SARCOMA; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CARCINOMA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE, NEOPLASM; GENETICS; HUMANS; IMMUNOLOGY; MACROPHAGES; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE, NEOPLASM; HUMANS; MACROPHAGES; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR MICROENVIRONMENT;

EID: 84921916858     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.01.002     Document Type: Review

References (91)

1. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
2. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222:155-161.
3. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
4. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
5. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
6. Komohara Y., Jinushi M., Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014, 105:1-8.
7. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2491-2496.
8. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
9. Su S., Liu Q., Chen J., Chen J., Chen F., He C., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014, 25:605-620.
10. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
11. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 2000, 164:762-767.
12. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65:11743-11751.
13. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
14. Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 2010, 11:936-944.
15. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
16. Satoh T., Kidoya H., Naito H., Yamamoto M., Takemura N., Nakagawa K., et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature 2013, 495:524-528.
17. Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V.C., et al. Functional polarization of tumor-associated macrophages by tumor-derived lactic acid. Nature 2014, 513:559-563.
18. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
19. Biswas S., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
20. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014, 344:921-925.
21. Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., Sio S.W., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:1-13.
22. Oshima H., Hioki K., Popivanova B.K., Oguma K., Van Rooijen N., Ishikawa T.O., Oshima M. Prostaglandin E2 signaling and bacterial infection recruits tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 2011, 40:596-607.
23. Schiechl G., Bauer B., Fuss I., Lang S.A., Moser C., Ruemmele P., et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. J. Clin. Invest. 2012, 121:1692-1708.
24. Doedens A., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 7:7465-7475.
25. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
26. Setafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64:6337-6343.
27. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
28. Baghdadi M., Yoneda A., Yamashina T., Nagao H., Komohara Y., Nagai S., et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013, 39:1070-1081.
29. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
30. Chao M.P., Alizadeh A.A., Tang C., Myklebust J.H., Varghese B., Gill S., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2009, 142:699-713.
31. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010, 24:241-255.
32. Shree T., Olson O.C., Elie B.T., Kester J.C., Garfall A.L., Simpson K., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2010, 25:2465-2479.
33. Daukin I., Eruslanov E., Stoffs T., Perrin G.Q., Algood C., Gilbert S.M., et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 2011, 71:6400-6409.
34. Bergenfelz C., Medrek C., Ekstrom E., Jirstrom K., Janols H., Wullt M., et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J. Immunol. 2012, 188:5448-5458.
35. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157:411-421.
36. Lawrence T., Bebien M., Liu G.Y., Nizet V., Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005, 434:1138-1143.
37. Luo J.L., Tan W., Ricono J.M., Korchynski O., Zhang M., Gonias S.L., et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446:690-694.
38. Squadrito M.L., Etzrodt M., Palma M.D., Pittet M.J. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol. 2013, 34:350-359.
39. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
40. Squadrito M.L., Pucci F., Magri L., Moi D., Gilfillan G.D., Ranghetti A., et al. miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep. 2012, 1:141-154.
41. Göktuna S.I., Canli O., Bollrath J., Fingerle A.A., Horst D., Diamanti M.A., et al. IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells. Cell Rep. 2014, 7:1914-1925.
42. Chen Y., Wang S.X., Mu R., Luo X., Liu Z.S., Liang B., et al. Dysregulation of the MiR-324-5p-CUEDC2 axis leads to macrophage dysfunction and is associated with colon cancer. Cell Rep 2014, 7:1982-1993.
43. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell Biol. 2013, 15:284-294.
44. Sonda N., Simonato F., Peranzoni E., Calì B., Bortoluzzi S., Bisognin A., et al. miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013, 38:1236-1249.
45. Xu S., Wei J., Wang F., Kong L.Y., Ling X.Y., Nduom E., et al. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J. Natl. Cancer Inst. J Natl Cancer Inst 2014, 106. (pii: dju162). 10.1093/jnci/dju162.
46. Zhang Q.W., Liu L., Gong C.Y., Shi H.S., Zeng Y.H., Wang X.Z., et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012, 7:e50946.
47. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Eng. J. Med. 2010, 362:875-885.
48. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011, 9:216.
49. Komohara Y., Horlad H., Ohnishi K., Fujiwara Y., Bai B., Nakagawa T., et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012, 103:2165-2172.
50. Komohara Y., Niino D., Saito Y., Ohnishi K., Horlad H., Ohshima K., et al. Clinical significance of CD163+ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013, 104:945-951.
51. Ritter M., Buechler C., Kapinsky M., Schmitz G. Interaction of CD163 with the regulatory subunit of casein kinase II (CKII) and dependence of CD163 signaling on CKII and protein kinase C. Eur. J. Immunol. 2001, 31:999-1009.
52. Hasita H., Komohara Y., Okabe H., Masuda T., Ohnishi K., Lei X.F., et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010, 101:1913-1919.
53. Jinushi M., Chiba S., Yoshiyama H., Masutomi K., Kinoshita I., Dosaka-Akita H., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12425-12430.
54. Zheng Y., Yang J., Qian J., Qiu P., Hanabuchi S., Lu Y., et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013, 27:702-710.
55. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
56. Jinushi M. Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses. Cancer Metastasis Rev. 2014, 33:737-745.
57. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2012, 1:54-67.
58. Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
59. Kodumudi K.N., Woan K., Gilvary D.L., Sahakian E., Wei S., Djeu J.Y. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010, 16:4583-4594.
60. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
61. Klug F., Prakash H., Huber P.E., Seibel T., Bender N., Halama N., et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24:589-602.
62. Taskinen M., Karjalainen-Lindsberg M.L., Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with tituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Can. Res. 2007, 13:5784-5789.
63. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
64. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 2013, 19:1035-1043.
65. Senovilla L., Aranda F., Galluzzi L., Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr. Opin. Immunol. 2014, 30C:24-31.
66. Jinushi M., Yagita H., Yoshiyama H., Tahara H. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol. Med. 2013, 19:536-545.
67. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
68. Cavnar M.J., Zeng S., Kim T.S., Sorenson E.C., Ocuin L.M., Balachandran V.P., et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J. Exp. Med. 2013, 210:2873-2886.
69. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, Bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
70. Pander J., Heusinkveld M., van der Straaten T., Jordanova E.S., Baak-Pablo R., Gelderblom H., et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 2011, 17:5668-5673.
71. Chen W., Ma T., Shen X., Xia X., Xu G., Bai X., Liang T. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012, 72:1363-1372.
72. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16:3420-3430.
73. Sprinzl M.F., Reisinger F., Puschnik A., Ringelhan M., Ackermann K., Hartmann D., et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013, 57:2358-2368.
74. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., et al. Macrophage colony-stimulating factor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132.
75. Brownlow N., Mol C., Hayford C., Ghaem-Maghami S., Dibb N.J. Dasatinib is a potent inhibitor of tumor-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009, 23:590-594.
76. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
77. Smith C.C., Lin K.L., Lasater E., Stewart W., Damon L., Kasarskis A., et al. Preclinical and clinical resistance mechanisms to the investigational selective FLT3 inhibitor PLX3397 in FLT3-IDT+acute myeloid leukemia (AML). Blood 2013, 122.
78. Ravi V., Wang W.L., Lewis V.O. (2011) Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr. Opin. Oncol. 2011, 23:361-366.
79. Kim T.S., Cavnar M.J., Cohen N.A., Sorenson E.C., Greer J.B., Seifert A.M., et al. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin. Cancer Res. 2014, 20:2350-2362.
80. Patwardhan P.P., Surriga O., Beckman M.J., de Stanchina E., Dematteo R.P., Tap W.D., Schwartz G.K. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Cancer Res. 2014, 20:3146-3158.
81. Mok S., Koya R.C., Tsui C., Xu J., Robert L., Wu L., et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74:153-161.
82. Strachan D.C., Ruffell B., Oei Y., Bissell M.J., Coussens L.M., Pryer N., Daniel D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology 2013, 2:e26968.
83. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
84. Fend L., Accart N., Kintz J., Cochin S., Revmann C., Le Pogam F., et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One 2013, 3:e73310.
85. Ries C.H., Cannarile M.A., Hoves S., Benz J., Wartha K., Runza V., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
86. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodeling. J. Pathol. 2013, 229:176-185.
87. Wang Y., Szretter K.J., Vermi W., Gilfillan S., Rossini C., Cella M., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 2012, 13:753-760.
88. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limon P. The polarization of immune cells in the tumor environment by TGF-beta. Nat. Rev. Immunol. 2010, 10:554-567.
89. Duluc D., Delneste Y., Tan F., Moles M.P., Grimaud L., Lenoir J., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
90. Pallasch C.P., Leskov I., Braun C.J., Vorholt D., Drake A., Soto-Feliciano Y.M., et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014, 156:590-602.
91. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironments to resistance. Cancer Cell 2012, 21:488-503.